Piper Jaffray Heartland Summit · 2013-08-12 · 3 1415 2013 Agenda The Minneapolis Club 729 Second...

Piper Jaffray Heartland Summit

AUGUST 14–15, 2013 IN MINNEAPOLIS

2

PIPER JAFFRAY HEARTLAND SUMMIT AUGUST 14–15, 2013

Contents

Agenda . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3

Piper Jaffray Healthcare Investment Research . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7

Piper Jaffray Sales and Trading Platform . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8

Piper Jaffray Healthcare Investment Banking . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9

Keynote Speaker . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10

State of the Industry CEO Panelist Biographies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11

Panelist Biographies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13

Piper Jaffray Senior Research Analyst Biographies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25

Attendee List . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30

Downtown Minneapolis Map . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34

Downtown Minneapolis Skyway Map . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35

Restaurant List . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36

Notes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37

Other Information

Wireless InternetComplimentary wi-fi is available throughout the club . Network is Minneapolis Club, no password required .

ParkingComplimentary parking is available in the Minneapolis Club Parking Ramp . Mention “Piper Jaffray” to the attendant upon exit .

QuestionsSubmit questions during the summit to heartland@pjc .com .

3


Agenda

The Minneapolis Club729 Second Avenue SouthMinneapolis, MN 55402

THE HEARTLAND SUMMIT

An annual gathering of leaders across all of healthcare to discuss the ideas shaping the industry . Featuring a unique panel-only format, industry leaders candidly discuss the major areas of growth, opportunity and controversy in healthcare . Investors and healthcare leaders gain a ‘Big Picture’ perspective on the current themes in healthcare, complemented by an annual rotation of focused discussions on selected major areas of opportunity in medical technology, therapeutics and healthcare services & IT .

HEARTLAND 2013

This year, we are pleased to have two never-before-seen panels of CEOs and CMOs from the world’s largest healthcare companies discussing the ‘State of the Industry’ in healthcare . In addition, our deep-dive discussions will cover some of the biggest ideas impacting the market, including predictive analytics in healthcare data, the increasing focus in pharma on hematological drugs, and emerging therapies in peripheral vascular devices .

Wednesday, August 14The Big Picture in Healthcare 9:00 – 9:45 a .m . Registration and Continental Breakfast – Main Dining Room, 3rd floor 9:45 – 10:00 a .m . Welcome and Opening Remarks: Andrew Duff, Chairman and CEO, Piper Jaffray 10:00 a .m . – 12:00 p .m . State of the Industry CEO Panel: The Big Picture from the Biggest Leaders Moderated by Brooks West, Senior Research Analyst, Piper Jaffray

A never-before-seen panel with the CEOs of the largest organizations across the entire healthcare landscape, discussing their views on innovation and value, mature vs . emerging market opportunities, acquisition strategies, changing global regulatory environments and significant controversies and opportunities impacting their businesses and the market .

• Neal Patterson, Chairman, President & CEO, Cerner Corporation (CERN)• Alex Gorsky, Chairman & CEO, Johnson & Johnson (JNJ)• George C . Halvorson, Chairman & CEO, Kaiser Permanente• Omar Ishrak, Chairman & CEO, Medtronic, Inc . (M .D .T)• Steve Hemsley, President & CEO, UnitedHealth Group (UNH)

12:00 – 12:30 p .m . Lunch Box lunches will be provided to enjoy during the Keynote Address

4


12:30 – 1:30 p .m . Lunch – Keynote Address: Governor Mike Leavitt, Founder and Chairman, Leavitt Partners, and Former Secretary, U.S. Department of Health and Human Services

After three terms as Governor of Utah, Administrator of the Environmental Protection Agency, and as the 20th Secretary of Health and Human Services, Michael Leavitt has an inside perspective on the role that government continues to play in the health sector . Most recently, Secretary Leavitt is working closely with several states as they implement the Patient Protection and Affordable Care Act . We look forward to hearing his unique perspectives on the challenges and opportunities in the healthcare market .

1:30 – 1:45 p .m . Break 1:45 – 2:45 p .m . Big Ideas in Healthcare Information Technology: Big Data

Moderated by Sean Wieland, Senior Research Analyst, Piper Jaffray

Big Data has the potential to truly reform healthcare by offering clinicians with insight to help make better decisions at the point of care . Big data and predictive analytics will refine and drive compliance with existing care protocols, and aid in the development of new ones . Whoever has the data and the mechanisms to deliver the clinical intelligence to the point of care will be the winners in this emerging technology .

• Jeff Townsend, EVP & Chief of Staff, Cerner Corporation (CERN) • Colin Hill, Chairman, CEO, President & Co-Founder, GNS Healthcare, Inc .• Andy Slavitt, Group Executive Vice President, Optum

2:45– 3:45 p .m . Big Ideas in Biotechnology: Advent of Patient Friendly Drugs for Oncology and Hematological MalignanciesModerated by M. Ian Somaiya, Senior Research Analyst, Piper Jaffray and Ted Tenthoff, Senior Research Analyst, Piper Jaffray

We will explore reasons for the increase in the number of drugs in development for the treatment of oncology and hematological malignancies . We will also discuss the potential of these targeted treatments to replace chemotherapy and turn cancer into a chronic disease with better patient outcomes .

• Kevin Koch, Ph .D ., President & Chief Scientific Officer, Array BioPharma Inc . (ARRY)

• Christopher P . Leamon, Ph .D ., Vice President, Research & Development, Endocyte, Inc . (ECYT)

• Julian Adams, Ph .D ., President, Research & Development, Infinity Pharmaceuticals, Inc . (INFI)

3:45 – 4:00 p .m . Break

5


4:00 – 5:30 p .m . State of the Industry CMO Panel: New Product StrategyModerated by Matt Miksic, Senior Research Analyst, Piper Jaffray and Brooks West, Senior Research Analyst, Piper Jaffray

With some of the most influential physicians in the world overseeing the R&D investment of billions of dollars, this discussion will focus on: criteria for new products including current and future economic and clinical hurdles; build vs . buy analyses and tensions/trade-offs between “innovation” and “value”; mature vs . emerging market product strategies; and evolving global regulatory environments .

• Mark A . Turco, M .D ., FACC, Chief Medical Officer, Vascular Therapies, Covidien plc (COV)

• Mark Carlson, M .D ., SVP & Chief Medical Officer Implantable Electronic Systems Division, St . Jude Medical Inc . (STJ)

• Richard Migliori, M .D ., EVP, Medical Affairs & Chief Medical Officer, UnitedHealth Group Incorporated (UNH)

5:30 – 6:00 p .m . Investment Banking M&A and Capital Markets Update and “Big Picture” Closing

Remarks: Jon Salveson, Vice Chairman, Investment Banking, Piper Jaffray 6:00 – 7:00 p .m . Cocktail Reception – Main Lounge Foyer, 2nd floor 7:00 p .m . Dinner – Main Lounge, 2nd floor

Thursday, August 15Big Ideas in Medical Device Technologies: Emerging Therapies in Peripheral Medicine

Day Two will consist of panel discussions on major therapeutic opportunities for device therapies in peripheral disease . In a twist this year, the panels will consist of company leaders and moderated by referring and target physicians . Each panel will also contain payor/provider participants . 7:00 – 8:00 a .m . Continental Breakfast – Main Dining Room, 3rd floor 8:00 – 10:00 a .m . Peripheral Vascular Disease (PVD) Panel Moderated by Brooks West, Senior Research Analyst, Piper Jaffray

Due to disease prevalence, more mature clinical data, and new reimbursement, PVD has returned as a significant therapeutic opportunity . Anticipated topics include drug-eluting balloons, peripheral stenting, atherectomy, and venous therapies .

6


• Jeff Mirviss, SVP & President, Peripheral Interventions, Boston Scientific Corporation (BSX)

• Stacy Enxing Seng, President, Vascular Therapies, Covidien plc (COV)• John DeFord, Ph .D ., SVP, Science, Technology & Clinical Affairs, C .R . Bard,

Inc . (BCR)• John McDermott, Chairman, President & CEO, Endologix Inc . (ELGX)• Sean Salmon, SVP & President, Coronary and Renal Denervation, Medtronic,

Inc . (M .D .T)• Scott Drake, President & CEO, Spectranetics Corporation (The) (SPNC)• Neil Hattangadi, M .D ., VP & GM, Peripheral Vascular, Volcano Corporation

(VOLC)

Participating physicians:• Lawrence Alexander Garcia, M .D ., Chief of Interventional Cardiology, St .

Elizabeth’s Medical Center; Co-Director, Vascular Medicine; Steward Health Care System

• Michael D . Horowitz, M .D ., MBA, National Medical Director, UnitedHealth Group Incorporated (UNH)

• Luis A . Sanchez, M .D ., FACS, Chief, Section of Vascular Surgery and Professor of Vascular Surgery, Washington University School of Medicine in St . Louis

10:00 – 11:00 a .m . Hypertension Panel Moderated by Brooks West, Senior Research Analyst, Piper Jaffray

Discussion of emerging device therapies in one of the largest potential untapped device therapeutic markets .

• Jeff Mirviss, SVP & President, Peripheral Interventions, Boston Scientific Corporation (BSX)

• Stacy Enxing Seng, President, Vascular Therapies, Covidien plc (COV)• Sean Salmon, SVP & President, Coronary and Renal Denervation, Medtronic,

Inc . (M .D .T)• Frank Callaghan, President, Cardiovascular and Ablation, St . Jude Medical

Inc . (STJ)

Participating physicians:• Lawrence Alexander Garcia, M .D ., Chief of Interventional Cardiology, St .

Elizabeth’s Medical Center; Co-Director, Vascular Medicine; Steward Health Care System

• Michael D . Horowitz, M .D ., MBA, National Medical Director, UnitedHealth Group Incorporated (UNH)

• Luis A . Sanchez, M .D ., FACS, Chief, Section of Vascular Surgery and Professor of Vascular Surgery, Washington University School of Medicine in St . Louis

11:00 a .m . Closing Remarks and Lunch Box lunches will be available prior to departures for off-site events, scheduled

company visits and airport .

7


Piper Jaffray Healthcare Investment Research

Dedicated to timely, fundamental market analysis

DEPTH AND BREADTH OF COVERAGE UNPARALLELED ON WALL STREET

The Piper Jaffray healthcare research team covers more than 190 large-, mid- and small-cap companies, delivering deep therapeutic category knowledge and deep industry experience .

Piper Jaffray Healthcare Research TeamDavid Amsellem Specialty PharmaceuticalsCharles Duncan Emerging BiopharmaceuticalsKevin Ellich Healthcare Services: Alternate Site ProvidersThom Gunderson Medical TechnologyMatt Miksic Medical Technology and Hospital SuppliesBill Quirk Medical Diagnostics and Life Science ToolsIan Somaiya BiotechnologyTed Tenthoff Drug DiscoveryBrooks West Medical Technology: Cardiovascular and DiversifiedSean Wieland Healthcare Services: Information Technology and Contract Research

ACCESS INDUSTRY LEADERS THROUGH INVESTOR EVENTS

10 Senior Healthcare Analysts

190+ Companies Covered

Conferences, Events & Corporate Access

• Each year Piper Jaffray hosts a Healthcare Conference, Heartland Summit and Catalyst Symposium

• Numerous conference calls with industry luminaries and physicians

• Webinars with renowned healthcare professionals throughout the year

• Topical lunches and roundtables discussions around healthcare industry conferences

• The corporate and institutional access team is comprised of a team of six individuals focused on non-deal roadshows

Technical Research

• Quarterly fundamental and technical webinars from Piper Jaffray technical strategist Craig Johnson, featuring the Piper Jaffray healthcare analysts

• Monthly Piper Jaffray Informed Investor conference calls, an overview of the broader market and sector-specific trends

The 25th Annual Piper Jaffray Healthcare Conference December 3-4, 2013 in New York City

This year’s conference will feature more than 250 of the most highly regarded and influential companies in the biotechnology, specialty pharmaceuticals, medical technology, medical diagnostics and devices, and healthcare services sectors .

• Over 1,400 attendees from the United States, Canada, Asia and Europe

• 2,300+ one-on-one meetings

• Interactive fireside chat format

• Panel discussions covering industry trends and challenges led by industry experts

8


San Francisco Los Angeles

London Zurich Minneapolis

Boston New York

Chicago

Our specialized distribution capabilities are led by a deep and experienced leadership based in each market

that serve the world’s top financial institutions.

Atlanta

Company Bookrunners Trading Rank

% of Total

Volume

Continued Research Coverage

First Financing Post IPO

#3 13% Bookrunner

#4 9% Dropped

#2 15% Bookrunner (Elevated Econs)

#1 33% Bookrunner

#2 17% Bookrunner (Left)

Deutsche Bank #1 28% Dropped

#2 14% –

#4 11% –

#3 13% –

PIPER JAFFRAY SALES AND TRADING PLATFORM

SP ECIALIZ ED DISTR IBUT IO N CAP ABIL I T I ES

CO MMITMENT TO AFTER M AR K E T SUP P O R T

100%

92% 91%

84% 83%

69%

59%

52% 50%48%

43% 42%

29%

21%

0%

25%

50%

75%

100%

Piper Jaffray

UBS / Schwab

BAML Jefferies Morgan Stanley

Cowen Goldman Sachs

Citi Baird JP Morgan

Wells Fargo

Deutsche Bank

Barclays RBC

% o

f IPO

s fo

r W

hich

Boo

krun

ner

is

a T

op T

hree

Tra

der

Senior Professional Region Tenure

Jeff Klinefelter, Global Head of Equities Global XX years

Jim Fehrenbach, Director of Equity Distribution Global 24 years

Tom O’Kane, Sales Manager New York 23 years

Scott Sullivan, Sales Manager Boston 26 years

Jim Sexton, Sales Manager Midwest 16 years

Bill Cook / Len Golbranson, Sales Manager West Coast 24 years / 16 years

Marc Ruddle, Sales Manager U.K. / Europe 19 years

More than 60 institutional sales and trading professionals covering the world’s top financial institutions in the U.S. and Europe with desks in the following locations:

Average sales tenure of 20+ years among regional sales managers

Piper Jaffray Sales and Trading Platform

SPECIALIZED DISTRIBUTION CAPABILITIES

More than 60 institutional sales and trading professionals covering the world’s top financial institutions in the U .S . and Europe with desks in the following locations:

San FranciscoLos Angeles

MinneapolisChicago

BostonNew York

LondonZurich

HoustonAtlanta

AVERAGE SALES TENURE OF 20+ YEARS AMONG REGIONAL SALES MANAGERS

SENIOR PROFESSIONAL TITLE REGION TENURE

Jeff Klinefelter Global Head of Equities Global 16 years Jim Fehrenbach Director of Equity Distribution Global 24 years Tom O’Kane Sales Manager New York 23 years Scott Sullivan Sales Manager Boston 26 years Jim Sexton Sales Manager Midwest 16 years Bill Cook / Len Golbranson Sales Manager West Coast 24 years / 16 years Marc Ruddle Sales Manager U .K . / Europe 19 years

COMMITMENT TO AFTERMARKET SUPPORT

San Francisco Los Angeles

London Zurich Minneapolis

Boston New York

Chicago

Our specialized distribution capabilities are led by a deep and experienced leadership based in each market

that serve the world’s top financial institutions.

Atlanta

Company Bookrunners Trading Rank

% of Total

Volume

Continued Research Coverage

First Financing Post IPO

#3 13% Bookrunner

#4 9% Dropped

#2 15% Bookrunner (Elevated Econs)

#1 33% Bookrunner

#2 17% Bookrunner (Left)

Deutsche Bank #1 28% Dropped

#2 14% –

#4 11% –

#3 13% –

PIPER JAFFRAY SALES AND TRADING PLATFORM

SP ECIALIZ ED DISTR IBUT IO N CAP ABIL I T I ES

CO MMITMENT TO AFTER M AR K E T SUP P O R T

100%

92% 91%

84% 83%

69%

59%

52% 50%48%

43% 42%

29%

21%

0%

25%

50%

75%

100%

Piper Jaffray

UBS / Schwab

BAML Jefferies Morgan Stanley

Cowen Goldman Sachs

Citi Baird JP Morgan

Wells Fargo

Deutsche Bank

Barclays RBC

% o

f IPO

s fo

r W

hich

Boo

krun

ner

is

a T

op T

hree

Tra

der

Senior Professional Region Tenure

Jeff Klinefelter, Global Head of Equities Global XX years

Jim Fehrenbach, Director of Equity Distribution Global 24 years

Tom O’Kane, Sales Manager New York 23 years

Scott Sullivan, Sales Manager Boston 26 years

Jim Sexton, Sales Manager Midwest 16 years

Bill Cook / Len Golbranson, Sales Manager West Coast 24 years / 16 years

Marc Ruddle, Sales Manager U.K. / Europe 19 years

More than 60 institutional sales and trading professionals covering the world’s top financial institutions in the U.S. and Europe with desks in the following locations:

Average sales tenure of 20+ years among regional sales managers

Our specialized distribution capabilities are led by adeep and experienced leadership team based in markets

serving the world’s top financial institutions.

Source: Dealogic & Autex Blockdata1. Autex Blockdata; Includes IPOs since 2006; Trading data is based on the first 12 months of trading; Data as of December 31, 2012

9


Piper Jaffray Healthcare Investment Banking

PIPER JAFFRAY HEALTHCARE INVESTMENT BANKING

R EP R ESENT A TIV E TR ANSAC TI O NS

2012 - YTD

10 M&A Advisories

6 Financings

$3.5+ Billion Aggregate Deal

Value

2012 - YTD

1 M&A Advisory

16 Financings


Value

2012 - YTD

7 M&A Advisories

3 Financings


Value

• Awarded “World’s Best Investment Bank – Healthcare Sector” by Global Finance in 2012

• Market leadership in healthcare M&A on Wall Street since 2010

• Bookrunner to market leaders across healthcare sectors

Highly Regarded Healthcare Franchise

• Full - service financing capabilities

• M&A advisor on hundreds of complex transactions

• Cross-border and emerging market expertise

• Investment professionals on three continents

Strategic Advisor Capabilities

Institutional Knowledge of Healthcare

• Decades of firm wide commitment to healthcare

• Capital markets and investment banking efforts devoted specifically to healthcare services, life sciences / biotech and medical technology

• Full breadth of research coverage

• Dedicated sales force and trading desk

Healthcare Services

Life Sciences / Biotech

Medical Technology

$ 92 ,000,000

Underwritten Registered Direct Offering 50 P R O FESSIO N A L S DEDICAT E D TO HEALT HC A R E

$325,000,000

Acquired by Baxter International

$1,298,000,000

Acquired by St. Jude Medical

$107,640,000

Initial Public Offering

$1,350,000,000

Acquired by Boston Scientific

$115,000,000


Undisclosed

Acquired by WCAS

$816,000,000

Acquired by Medtronic

$36,410,000

Underwritten Registered Direct Offering

$ 66 ,000,000


$307,000,000

Acquired by athenahealth

$310,000,000

Acquired by Abbott

HIGHLY REGARDED HEALTHCARE FRANCHISE• Awarded “World’s Best Investment Bank – Healthcare Sector” by

Global Finance in 2012 and 2013.• Leader on Wall Street in healthcare M&A since 2010• Bookrunner to market leaders across healthcare sectors• Leader in Medical Technology IPO advisories since 2004

STRATEGIC ADVISOR CAPABILITIES• Full-service financing capabilities• M&A advisor on hundreds of complex transactions• Cross-border and emerging market expertise• Investment professionals on three continents

INSTITUTIONAL KNOWLEDGE OF HEALTHCARE• Decades of firm wide commitment to healthcare• Capital markets and investment banking efforts devoted specifically to

healthcare services, life sciences / biotech and medical technology• Full breadth of research coverage• Dedicated sales force and trading desk

50 PROFESSIONALS DEDICATED TO HEALTHCARE

REPRESENTATIVETRANSACTIONS

Healthcare Services

2012 – 2013 YTD

7 M&A Advisories

4 Financings


Value

Life Sciences/ Biotech

2012 – 2013 YTD

4 M&A Advisory

35 Financings


Value

Medical Technology

2012 – 2013 YTD

13 M&A Advisories

8 Financings


Value

10


Michael LeavittFormer U .S . Secretary of Health and Human Services

Michael Leavitt is the founder of Leavitt Partners, a consulting firm that advises clients in the healthcare and food safety sectors . The firm is deeply involved in helping states implement the Patient Protection and Affordable Care Act, commonly known as “ObamaCare .”

Leavitt’s career in public service began when he was elected the 14th governor of Utah in 1993 . Leavitt was re-elected in 1996 with the largest vote total in state history . In 2000, Leavitt became only the second governor in Utah history to be re-elected to a third term . As governor, he held leadership positions in national and regional organizations, such as the Council of State Governments, over which he presided for a year .

In 2003, President George W . Bush nominated Leavitt as administrator of the Environmental Protection Agency . Confirmed by an overwhelming vote in the Senate of 88–8, Leavitt was sworn in as the 10th administrator of the EPA . At the Environmental Protection Agency, he implemented higher standards for ozone, diesel fuels and other air pollutants . He organized and managed a collaboration to develop a federal plan to clean up the Great Lakes .

In December 2004, Leavitt was nominated by President Bush to succeed Tommy Thompson as secretary of Health and Human Services . Leavitt was sworn in shortly thereafter as the 20th secretary of Health and Human Services . Leavitt has described the avian influenza virus as the most serious threat to American security . As H .H .S . secretary, Leavitt is known for his work in mobilizing the nation’s pandemic preparedness leading to the reconfiguring of the nation’s medical emergency plans .

Keynote Speaker

11


State of the Industry CEO Panelist Biographies

Alex Gorsky Johnson & JohnsonChairman & CEO

Alex Gorsky is the chairman and CEO of Johnson & Johnson, the world’s largest diversified healthcare products company and component of the Dow Jones Industrial Average, with 128,000 employees and revenues approaching $70 billion . After spending six years in the U .S . Army, Gorsky joined J&J as a sales representative in 1988 . After briefly leaving the company to serve as head of Pharmaceuticals at Novartis, Gorsky returned to J&J and became worldwide chairman of the medical devices and diagnostics group in 2009, vice chairman of the executive committee in 2011, and CEO in April 2012 . In his time as CEO, Gorsky has overseen several key M&A transactions, notably the J&J purchase of Synthes Inc . in 2012 . In 2012, Gorsky was named to Modern Healthcare’s annual list of 100 Most Influential people in healthcare .

George Halvorson Kaiser PermanenteChairman & CEO

George Halvorson is the chairman and CEO from 2002 to 2013 of Kaiser Permanente, one of the largest medical organizations in the United States, with 37 medical centers, 611 medical offices, nearly 9 million health plan members, 175,668 employees and revenues of almost $50 billion . Halvorson joined Kaiser from HealthPartners, where he was CEO for 18 years . Halvorson has served on the Institute of Medicine Roundtable on Value & Science-Driven Health Care, the IOM Task Force on Making America a Learning Health Care Organization, the American Hospital Association’s Advisory Committee on Health Reform, the Commonwealth Fund Commission on a High Performance Health System and the New America Foundation Leadership Council . In 2012, Halverson was named No . 6 on Modern Healthcare’s annual list of 100 Most Influential people in healthcare .

Stephen HemsleyUnitedHealth Group IncorporatedPresident & CEO

Stephen Hemsley is president and CEO of UnitedHealth Group, the world’s largest health carrier and largest health information company, with over 130,000 employees and revenues exceeding $110 billion . Hemsley joined the company in 1997 as senior executive vice president and was later named COO in 1998 . Most recently, Hemsley has overseen the acquisition of Amil in Brazil, the largest emerging market acquisition in the industry . Prior to joining UnitedHealth Group, Hemsley served as the managing partner in strategy and planning and CFO of Arthur Anderson . During his tenure as CEO, UnitedHealth has been consistently named the Most Admired Company in its sector by Forbes, has risen to No . 17 in the Fortune 500, and been added as a component of the Dow Jones Industrial Average . In 2012, Hemsley was named No . 7 on Modern Healthcare’s annual list of 100 Most Influential people in healthcare .

12


Omar Ishrak Medtronic, Inc .Chairman & CEO

Omar Ishrak is the current chairman and CEO of Medtronic, the world’s largest medical device company, with more than 45,000 employees and revenues approaching $17 billion . Before joining Medtronic as CEO in 2011, Ishrak spent 16 years as president and CEO of GE Healthcare, where he was responsible for businesses ranging from ultrasound to cardiology and life support solutions . Ishrak was instrumental in positioning GE to become the world’s leading provider of ultrasound technology and services, growing revenues fourfold under his watch . Since becoming CEO of Medtronic, Ishrak has overseen key M&A transactions, notably the Medtronic acquisitions China Kanghui, the largest emerging-market medical device acquisition in the industry .

Neal Patterson Cerner CorporationChairman, President & CEO

Neal Patterson is the president, CEO and chairman of Cerner Corporation, the world’s largest independent health information technology company, with 11,900 employees and revenues of $3 billion . Patterson co-founded the company in 1979, focusing initially on creating a suite of fully integrated healthcare applications, and later on rebuilding the platform on client-server technology . He took the company public in 1986 and has ambitiously spent over $3 billion on R&D and creating solutions that have been deployed at more than 2,700 hospitals . Patterson has been named five times as one of Modern’s Healthcare’s “100 Most Powerful People in Healthcare,” and in 2012 was named by Forbes as one of America’s Best CEOs .

13


Julian AdamsPresident, Research and DevelopmentInfinity Pharmaceuticals, Inc .

Julian Adams, Ph .D ., is president, research and development for Infinity Pharmaceuticals . Adams is responsible for the full spectrum of Infinity’s drug discovery, preclinical and clinical development strategy, and regulatory affairs activities .

Prior to joining Infinity in 2003, Adams was the senior vice president, drug discovery and development at Millennium Pharmaceuticals . In this capacity, he had global responsibility for multiple drug discovery programs, including the successful discovery and development of Velcade® (bortezomib), a proteasome inhibitor for cancer therapy . He joined Millennium through its acquisition of LeukoSite in 1999 where he was senior vice president research and development . Adams joined LeukoSite as a result of its acquisition of ProScript, Inc ., where he had served as a member of the founding management team, executive vice president of research and development, and a member of the board of directors . Earlier in his career, Adams served in various positions, including director, medicinal chemistry at Boehringer Ingelheim, where he successfully discovered the drug Viramune® (nevirapine) for HIV . Also, from 1982-1987, he was a medicinal chemist at Merck .

Adams has received many awards, the 2012 Warren Alpert Foundation Prize for his role in the discovery and development of bortezomib, the 2012 C . Chester Stock Award Lectureship from Memorial Sloan-Kettering Cancer Center, and the 2001 Ribbon of Hope Award for Velcade® from the International Myeloma Foundation . Adams is an inventor of more than 40 patents and has authored over 100 papers and book chapters in peer-reviewed journals . He is the editor of Proteasome Inhibition in Cancer Therapy, published in July 2004 .

Adams received his bachelor’s degree from McGill University and his Ph .D . from the Massachusetts Institute of Technology in the field of synthetic organic chemistry . He also received the degree of Doctor of Science, honoris causa, from McGill University in 2012 .

Panelist Biographies

14


Frank CallaghanPresident, Cardiovascular and Ablation Technologies DivisionSt . Jude Medical

Frank Callaghan became president of the St . Jude Medical cardiovascular and ablation technologies division in August 2012 . He had previously served as president of the company’s cardiovascular division since 2008 . Callaghan joined St . Jude Medical as vice president of research and development for the atrial fibrillation division in 2005 as part of the Endocardial Solutions acquisition .

At Endocardial Solutions, Callaghan spent 10 years as vice president of research and development . In this role, he led R&D activities from early-stage conception through clinical trials into market launches . Callaghan previously held senior roles with Telectronics Pacing Systems and Cordis Corporation .

Callaghan holds a master’s degree in electrical engineering and a master’s degree in biological sciences from Purdue University . He holds more than 20 patents in cardiovascular devices .

Mark D. Carlson, M.D. Chief Medical Officer and Senior Vice President

Research and Clinical Affairs

Mark Carlson, M.D.Chief Medical Officer and Senior Vice President, Research and Clinical AffairsSt . Jude Medical

Mark Carlson is chief medical officer and senior vice president, research and clinical affairs, in the St . Jude Medical implantable electronic systems division .

Carlson trained in internal medicine at University Hospitals of Cleveland and Case Western Reserve University and in cardiology and cardiac electrophysiology at the Massachusetts General Hospital and Harvard University . He joined the faculty of Case Western Reserve University in 1988 and remains on faculty as adjunct professor of medicine . His research on arrhythmias and neural control has resulted in more than 150 publications . As a Robert Wood Johnson fellow on Senator Orrin Hatch’s Senate Judiciary Committee, Carlson worked on the Medicare Prescription Drug, Improvement and Modernization Act and the Cord Blood Stem Cell Act . Thereafter, he returned to Case as associate vice president, government relations . Carlson served on the FDA’s Devices Dispute Resolution Panel, the NCDR ICD registry steering committee, and chaired the HRS Health Policy Committee, the ACC Electrophysiology Committee, the HRS/FDA Policy Conference on Device Performance, and the HRS task force on device performance policies and guidelines and the Medicare Evidence Development & Coverage Advisory Committee .

Carlson serves on the board of California Healthcare Institute, is an executive board member and vice president, administration for the West Los Angeles Council of the Boy Scouts of America, and a member of the Dean’s Advisory Council at Kansas State University . Carlson received his M .D . from the University of Kansas and a master’s degree in public policy from Duke University .

15


John DeFordSenior Vice President, Science, Technology and Clinical AffairsC . R . Bard, Inc .

John DeFord was appointed senior vice president, science, technology and clinical affairs at C . R . Bard, Inc . in 2007 . He joined the company as vice president of science and technology in January 2004 . Prior to joining C . R . Bard, DeFord was managing director of Early Stage Partners, a Midwest venture capital fund . Prior to joining Early Stage Partners, he was president and CEO of Cook Incorporated, a multi-hundred million dollar privately held medical device manufacturer .

DeFord is a graduate of Purdue University with a bachelor’s degree and master’s degree in electrical engineering and a Ph .D . in electrical/biomedical engineering .

DeFord holds 13 patents and is the author of numerous peer-reviewed scientific papers and book chapters .

Scott DrakeChief Executive OfficerSpectranetics Corporation

Scott Drake was appointed chief executive officer of Spectranetics in August 2011 .

Prior to joining Spectranetics, Drake held the position of senior vice president, Operations of DaVita, Inc . (NYSE: DVA), a leading U .S . provider of kidney care and dialysis . At DaVita, he had responsibility for business operations that generated approximately 20% of the company’s revenue, which exceeds $6 billion .

Previously, Drake held several positions of increasing responsibility within various healthcare business units at Covidien, Plc over a period of 17 years . From 2006 to 2009, Drake was global business unit president, respiratory and monitoring solutions, a $1 .5 billion business with 8,000 employees . Under his leadership, significant operational improvements were made, including revenue and profit growth; enhanced new product development pipeline; lifting of FDA consent decree; and lean six sigma operational excellence initiatives . Foundational to these accomplishments is an intense focus on new product development, organizational effectiveness and customer needs . From 2003 to 2006, he was president, Valleylab (recently renamed Energy-Based Devices), a $375 million surgical device business, where organic revenue growth accelerated from 4% to 24% during his tenure . From 2001 to 2003, he was vice president and general manager, critical care, a $150 million business unit where revenue growth and operating profitability improved under his leadership . Prior to 2001, Drake held several positions in sales and marketing management within various medical device business units .

Drake holds a bachelor’s degree in business administration from Miami University of Ohio .

16


Andrew DuffChairman and CEOPiper Jaffray Companies

Andrew Duff became chairman and chief executive officer of Piper Jaffray Companies following completion of our spin-off from U .S . Bancorp on December 31, 2003 . He also has served as chairman of our broker-dealer subsidiary since 2003, as chief executive officer of our broker-dealer subsidiary since 2000 . Duff joined the Piper Jaffray institutional fixed income sales department in 1980 and was promoted to manager of institutional sales and trading in 1994 . He then served as president of the individual investor services and capital markets areas until 1996 . From 1996 through 2003, Duff served as president of Piper Jaffray and vice chair of U .S . Bancorp for the wealth management group from 1999 through 2003 .

Duff holds a bachelor’s degree in economics from Tufts University in Medford, Mass ., and attended the Advanced Executive Program at the J .L . Kellogg Graduate School of Management at Northwestern University .

Duff currently serves on the board of directors of the Securities Industry and Financial Markets Association (SIFMA), the University of St . Thomas board of trustees and the University of St . Thomas Opus College of Business strategic board of governors . He is the president of the Walker Art Center board of trustees, and is an advisor to the board of directors of Great Clips, Inc .

Stacy Enxing Seng President Vascular Therapies, Covidien

Stacy Enxing SengPresident, Vascular TherapiesCovidien

Stacy Enxing Seng, president, vascular therapies, is responsible for Covidien’s full portfolio of vascular products, composed of two broad product categories: peripheral vascular and neurovascular . The peripheral vascular business is comprised of three global franchises: endovenous (peripheral arterial stents, balloons and atherectomy, and devices for the treatment of chronic venous insufficiency (CVI)), renal denervation (therapeutic device for the treatment of resistant hypertension) and venous solutions (dialysis catheters and compression devices for the prevention of deep vein thrombosis (DVT)) . The neurovascular portfolio includes liquid embolics, embolization coils, flow diversion, thrombectomy catheters and occlusion balloons .

Prior to this role, Enxing Seng was president, peripheral vascular, responsible for the full portfolio of peripheral vascular products within the vascular therapies global business unit . Enxing Seng joined Covidien in July 2010 through the acquisition of ev3, a $500 million business, where she was a founding member and executive officer responsible for leading ev3’s peripheral vascular division from inception to a $350 million business . Enxing Seng has also held various positions of increasing responsibility for Boston Scientific, SCIMED Life Systems Inc ., Baxter Healthcare and American Hospital Supply .

Enxing Seng received a bachelor’s degree from Michigan State University and a Master of Business Administration degree from Harvard University .

17


Lawrence Alexander Garcia, MD Chief of Interventional Cardiology, St. Elizabeth's Medical Center; Co-Director, Vascular Medicine

Luis A Sanchez, MD, FACS Current Position Professor, Surgery Section Head, Division of General Surgery, Vascular Surgery Section

Lawrence Garcia Chief of Interventional Cardiology and Vascular InterventionsSt . Elizabeth’s Medical Center

Dr . Lawrence Garcia is chief of interventional cardiology and vascular interventions at St . Elizabeth’s Medical Center in Boston, Massachusetts and an associate professor of medicine at Tufts University School of Medicine . He is also the director of the interventional cardiology fellowship and director of the vascular medicine program at St . Elizabeth’s .

Garcia received his training in cardiology at the University of Iowa Hospitals and Clinics in Iowa City, Iowa and as an interventional cardiologist at the Beth Israel Deaconess Medical Center at Harvard Medical School . Garcia then received his peripheral vascular training at St . Elizabeth’s Medical Center . Garcia served at the Beth Israel Hospital as a full-time interventional cardiologist and director of the peripheral cardiovascular program and peripheral interventions at the Beth Israel Deaconess Medical Center, as well as the director of the interventional fellowship program .

Garcia continues his research interests in a wide variety of studies including peripheral vascular interventional trials and has served as national or global principal investigator on several trials, including a study evaluating either directional atherectomy or a novel nitinol stent for treatment of lower extremity arterial obstructive disease . Garcia has also been involved with clinical studies focused on the assessment of transthoracic impedance as it relates to trans-thoracic defibrillation and the effect that higher perimeter impedance pads have on skin damage following direct current cardioversion . He is widely regarded as an expert in peripheral vascular disease, specifically in atherectomy for lower extremity revascularization as well as the scientific data-set for lower limb revascularization strategies . His work has been presented in numerous manuscripts, abstracts, textbooks and textbook chapters .

Neil Hattangadi, M.D.Vice President and General Manager, Peripheral Vascular Business UnitVolcano Corporation

Neil Hattangadi has served as vice president and general manager of the peripheral vascular business unit since October 2012 .

Prior to this role, Hattangadi served as vice president and business unit leader, intravascular therapies . He joined Volcano in July 2011 as vice president, functional measurement and image guided therapies . From 2008 to 2011, Hattangadi was a healthcare equities investor at hedge funds including Citadel Asset Management and SAC Capital . He previously served as vice president, molecular programs and FoxHollow clinical affairs at ev3 Inc ., joining the company through the acquisition of FoxHollow Technologies, Inc . He was also a consultant with McKinsey and Company in their Boston and Silicon Valley offices .

Hattangadi received a bachelor’s degree from Duke University, a master’s degree from Oxford University as a Rhodes Scholar, and a M . D . from Harvard University .

18


a director at Capella University (NASDAQ: CPLA) where he is chair of the compensation committee. Slavitt graduated from the Wharton School and The College of Arts & Sciences at the University of Pennsylvania, and received his Master of B usiness Administration degree from the Harvard Business School.

Colin Hill CEO, PRESIDENT, CHAIRMAN, AND CO-FOUNDER Colin Hill co-founded GNS Healthcare in 2000 and has served as CEO since then. He brings years of hands-on scientific experience to his role, with expertise in the areas of computational physics and systems biology. He also serves as Chairman of GNS Healthcare’s parent company Via Science, a leading big data analytics company focused on business intelligence, finance, and economic forecasting. He also serves on the Board of Directors of AesRx, a biopharmaceutical company dedicated to the development of a new treatment for sickle cell disease. Colin serves on the Advisory Board of the Boston Medical Center’s philanthropic trust and as the Chair of the Industrial Advisory Board of EBICS. Colin is the author of the “Healthcare 2020” blog on Forbes.com.

In 2004, Colin was named to MIT Technology Review’s TR100 list of the top innovators in the world under the age of 35. He is a frequent speaker at international scientific and industry conferences and has appeared in numerous publications and television segments, including The Wall Street Journal, CNBC Morning Call, Nature, Forbes, Wired, and The Economist. He graduated from Virginia Tech with a degree in physics and earned masters degrees in physics from McGill University and Cornell University.

Colin HillCEO, President, Chairman and Co-FounderGNS Healthcare, Inc .

Colin Hill co-founded GNS Healthcare in 2000 and has served as CEO since then . He brings years of hands-on scientific experience to his role, with expertise in the areas of computational physics and systems biology . He also serves as chairman of GNS Healthcare’s parent company Via Science, a leading big data analytics company focused on business intelligence, finance and economic forecasting .

Hill also serves on the board of directors of AesRx, a biopharmaceutical company dedicated to the development of a new treatment for sickle cell disease . He serves on the advisory board of the Boston Medical Center’s philanthropic trust and as the chair of the industrial advisory board of EBICS . Hill is also the author of the “Healthcare 2020” blog on Forbes .com .

MICHAEL D. HOROWITZ, MD, MBA National Medical Director UnitedHealth Group

Michael D. Horowitz, MD, MBA, is National Medical Director for UnitedHealth Group. He is responsible for the clinical executive leadership and oversight of national accounts. Prior to joining UnitedHealth Group, Dr. Horowitz was President of Medical Insights International, a health care consulting firm recognized for its expertise in international medical travel. A graduate of the University of Miami School of Medicine, Dr. Horowitz completed specialty training in Surgery and in Cardiothoracic Surgery. After serving on the Surgical Faculty of the University of Miami School of Medicine for several years, Dr. Horowitz developed and managed a highly successful cardiac surgery program in a community hospital that previously did not have these services.

Dr. Horowitz is a Diplomate, Fellow or member of numerous professional medical and surgical organizations. He is certified by the American Board of Surgery and the American Board of Thoracic Surgery. He is also a Certified Physician Executive. Dr. Horowitz received an MBA with concentration in Organization and Management from the Goizueta Business School of Emory University in 2006. He is a member of Beta Gamma Sigma International Business Honor Society. A sought-after speaker, Dr. Horowitz has given numerous professional presentations for diverse audiences. He is the author of many published articles covering a broad spectrum of topics.

Michael Horowitz, M.D.National Medical DirectorUnitedHealth Group

Michael Horowitz is national medical director for UnitedHealth Group, responsible for clinical executive leadership and oversight of national accounts .

Prior to joining UnitedHealth Group, Horowitz was President of Medical Insights International, a healthcare consulting firm recognized for its expertise in international medical travel .

A graduate of the University of Miami School of Medicine, Horowitz completed specialty trainingin surgery and in cardiothoracic surgery . After serving on the surgical faculty of the University of Miami School of Medicine for several years, Horowitz developed and managed a highly successful cardiac surgery program in a community hospital that previously did not have these services .

Horowitz is a diplomate, fellow or member of numerous professional medical and surgical organizations . He is certified by the American Board of Surgery and the American Board of Thoracic Surgery . He is also a Certified Physician Executive .

Horowitz received a Master of Business Administration degree with concentration in organization and management from the Goizueta Business School of Emory University in 2006 . He is a member of Beta Gamma Sigma International Business Honor Society .

19


Kevin Koch, Ph.D.President & Chief Scientific OfficerArray BioPharma Inc .

Kevin Koch is a co-founder of Array and has served as president, chief scientific officer and a member of the board of directors since May 1998 .

Prior to forming Array, Koch was an associate director of medicinal chemistry and project leader for the protease inhibitor and new leads project teams for Amgen, Inc . from 1995 to 1998 . From 1988 until 1995, Koch held various positions with Pfizer Central Research, including senior research investigator, project coordinator for the cellular migration and immunology project teams . From 1998 until 2003, Koch was an elected board member of the Inflammation Research Association .

Koch received a bachelor’s degree in chemistry and biochemistry from the State University of New York at Stony Brook, and a Ph .D . in synthetic organic chemistry from the University of Rochester .

Christopher Leamon Vice President of Research & DevelopmentEndocyte, Inc .

Christopher Leamon, Ph .D . has served as Endocyte’s vice president of research and development since April 2000 . From February 1999 to April 2000, Leamon served as director of biology and biochemistry .

Prior to joining Endocyte, Leamon was employed in the pharmaceutical industry where he conducted discovery research in the field of peptide, oligonucleotide, liposome and DNA drug delivery for GlaxoWellcome, a healthcare company and Isis Pharmaceuticals, a biomedical pharmaceutical company .

Leamon holds a bachelor’s degree in chemistry from Baldwin Wallace College and a Ph .D . in biochemistry from Purdue University .

20


John McDermottChairman of the Board, President and Chief Executive OfficerEndologix, Inc .

John McDermott joined Endologix in May 2008 as president and chief executive officer . McDermott has more than 20 years of executive management, sales, marketing and finance experience in the vascular device industry .

From 2002 to 2007, McDermott served as president of Bard Peripheral Vascular, a division of C . R . Bard, Inc . He previously served as president of global sales for C .R . Bard’s vascular surgery and endovascular businesses with responsibilities for managing a worldwide direct sales force with more than 200 representatives . Prior to that, he served for four years as president of C .R . Bard’s division IMPRA, Inc ., where he was responsible for global operations, including sales, marketing, research and development, manufacturing, and finance . From 1990 to 1996, McDermott served as chief financial officer and later vice president and chief operating officer of IMPRA, Inc ., prior to its acquisition by C . R . Bard .

McDermott is an active leader within the vascular community and is currently on the board of directors of the International Society of Endovascular Specialists .

Richard Migliori, M.D.Executive Vice President, Medical Affairs and Chief Medical OfficerUnitedHealth Group

In 2013, Richard Migliori was appointed executive vice president, medical affairs, and chief medical officer for UnitedHealth Group, working with businesses across the enterprise to help improve healthcare quality, access and affordability .

Previously, as executive vice president for health services, Migliori was responsible for the ongoing development, design and adaptation of market leading clinical innovations aimed at ensuring clinical excellence, improving clinical and economic outcomes, and delivering robust business performance on behalf of UnitedHealth Group’s largest public and private sector clients .

21


Jeff MirvissSenior Vice President and President, Peripheral InterventionsBoston Scientific Corporation Jeff Mirviss is senior vice president and president, peripheral interventions for Boston Scientific and a member of its executive committee . In that capacity, he is responsible for developing and bringing to market innovative solutions for treating patients with high blood pressure, vascular system blockages and cancer .

Mirviss has more than 23 years of experience in medical device and pharmaceutical general management, marketing and sales . He has held positions of increasing responsibility since 1997 at Boston Scientific . In addition to his roles at Boston Scientific, Mirviss has worked for companies ranging in size from a pre-revenue venture-backed medical device startup to Dow 30 companies .

Mirviss holds a bachelor’s degree from the University of Minnesota and a Master of Business Administration degree from the University of St . Thomas .

Sean Salmon SVP and President Coronary & Renal Denervation (RDN)

Sean Salmon is the SVP and President for the Coronary and Renal Denervation (RDN) businesses. Sean joined Medtronic Vascular as the Global Vice President of Coronary and Peripheral Marketing on November, 2004. He was promoted to General Manager of the Coronary and Peripheral business in October 2007 and promoted to SVP and President for the Coronary and Renal Denervation (RDN) in July 2011.

Sean has over 23 years of successful experience in the pharmaceutical and medical device industries. He has held positions of increasing responsibility at CR Bard, Johnson & Johnson Interventional Systems, Cordis/JNJ, SurgiVision and EuroRSCG Life.

He earned an MBA from the Kellogg School of Management at Northwestern University and a BS in Applied Physiology from Boston University.

Sean SalmonSenior Vice President and President, Coronary & Renal Denervation (RDN)Medtronic, Inc . Sean Salmon is senior vice president and president for the coronary and renal denervation (RDN) businesses . Salmon joined Medtronic Vascular as the global vice president of coronary and peripheral marketing on November 2004 . He was promoted to general manager of the coronary and peripheral business in October 2007 and promoted to senior vice president and president for the coronary and renal denervation (RDN) in July 2011 .

Salmon has over 23 years of successful experience in the pharmaceutical and medical device industries . He has held positions of increasing responsibility at C . R . Bard, Johnson & Johnson Interventional Systems, Cordis/JNJ, SurgiVision and EuroRSCG Life .

Salmon earned an Master of Business Administration degree from the Kellogg School of Management at Northwestern University and a bachelor’s degree in applied physiology from Boston University .

22


Jon SalvesonVice Chairman, Investment BankingPiper Jaffray & Co .

Jon Salveson is the vice chairman of Piper Jaffray investment banking . Prior to his current position, Salveson was the global head of investment banking for seven years . He is involved in a full range of investment banking activities, including public and private equity and debt financings, M&A advisories and financial advisory services . Prior to leading the investment banking effort, Salveson spent his career at Piper Jaffray building a leading healthcare underwriting and M&A advisory practice . In 1996, Salveson opened the Piper Jaffray office in Menlo Park, Calif ., where he was instrumental in establishing a large technology and healthcare presence in Silicon Valley, including over 100 investment banking and research professionals .

Prior to joining Piper Jaffray, Salveson was a product manager at a biotechnology firm .

Salveson graduated from St . Olaf College and received a Master of Management degree from the J .L . Kellogg Graduate School of Management at Northwestern University . He serves on the executive committee of the board of the Minnesota Orchestra, and is a member of the board of regents at St . Olaf College .

Lawrence Alexander Garcia, MD Chief of Interventional Cardiology, St. Elizabeth's Medical Center; Co-Director, Vascular Medicine

Luis A Sanchez, MD, FACS Current Position Professor, Surgery Section Head, Division of General Surgery, Vascular Surgery Section

Luis Sanchez Chief of Vascular SurgeryWashington University School of Medicine

Dr . Luis Sanchez is chief of vascular surgery at the Washington University School of Medicine in St . Louis, Missouri . Sanchez also serves as the Gregorio A . Sicard Distinguished Professor of Surgery and Radiology and the program director of the vascular fellowship at Washington University School of Medicine .

Sanchez received his medical training from Harvard Medical School and his training in surgery at the Montefiore Medical Center/Albert Einstein College of Medicine in New York, where he served as chief resident . He subsequently received his vascular surgery fellowship training at Montefiore Medical Center . Sanchez is widely regarded as an expert in endovascular and vascular surgery, and has been an investigator in at least 35 clinical trials, including most recently as the National Principal Investigator of Medtronic’s VITALITY Trial, a post-marketing evaluation of the Talent endovascular graft, and as a co-investigator in Cook’s Zenith Fenestrated Trial and the company’s Zenith LP Trial . He has also recently served as a co-investigator of CVRx’s HOPE4HF trial of the RHEOS device in congestive heart failure and as a co-investigator of Endologix’s bifurcated Powerlink System .

Sanchez continues his research interests in a wide variety of studies including treatment of abdominal aortic aneurysms (AAAs) . His work has been published in numerous journals, abstracts, textbooks and textbook chapters, and Sanchez has participated in numerous panels, presentations, and committees, including as chairman of the TriVascular clinical events committee and as a member of the FEVAR writing group within the Society for Vascular Surgery .

23


Jeffrey Townsend, executive vice president, chief of staff, is responsible for a wide swath of Cerner business, including supervision of Cerner LifeSciences, Healthe™ Employer, and much of Cerner’s cloud computing effort, the foundation for our consumer presence. These market initiatives are referred to as CERN—an acronym for Consumer, Employer, Research and Networks—and are critical to Cerner’s vision for population health. The CERN structure also encompasses Cerner’s Revenue Cycle, EMEA (Europe, Middle East and Africa) and Lighthouse clinical process improvement organizations, to establish future strategic alignment between U.S. and European health care systems. Townsend is also the senior executive responsible for the Tiger Institute and the University of Missouri Health System, Cerner’s second charterITWorks™ client. He also oversees Catalyst, an organization that works across Cerner supporting front line teams and clients with a blend of education, communication and marketing expertise. Additionally, Townsend focuses much of his time on the innovation, strategy and direction of Cerner solutions, financial planning and overseeing the company’s day-to-day operations as CEO Neal Patterson’s proxy. Townsend joined Cerner in 1985 as a programmer analyst, and within one year, he was named project leader of the foreign systems interface engineering team. After leaving Cerner for several years to lead a family-owned business, Townsend rejoined the company as project manager for strategic systems and product line executive for Cerner’s management systems. He also served as the chief engineering officer, where he oversaw product development of Cerner Millennium® “I am proud of what we have achieved with Millennium, but I believe there are more big ideas yet to come,” Townsend said. “After more than 30 years, Cerner is in a unique position to be able to help define and create an ideal future state where health care is simplified by connecting individuals, providers, researchers and employers to impact health outcomes.” Townsend earned a bachelor’s degree in computer science from Iowa State University.

Andy Slavitt Group Executive Vice President Andy Slavitt is group executive vice president at Optum, where he is responsible for Optum’s business strategy, public policy, corporate investment, research and development, acquisitions and corporate governance. Prior to this role, Slavitt was CEO of OptumInsight from 2006 through 2011and has served in other roles at UnitedHealth Group, such as leading the consumer solutions business and co-chairing UnitedHealth Group’s Innovation Council.

Previously, Slavitt was founder and CEO of Health Allies, which was acquired by UnitedHealth Group in 2003. He also has worked as a strategy consultant with McKinsey & Company and as an investment banker with Goldman Sachs. Slavitt serves in a number of advocacy and board capacities in health care, education and the community. He is a senior advisor to Hope Street Group; on the steering committee of the Itasca Project; on the Major Gift Committee at the University of Pennsylvania, where he also was co-chair of annual giving; serves on the board of directors of the Guthrie Theatre; and is

Andy Slavitt Group Executive Vice PresidentOptum

Andy Slavitt is group executive vice president at Optum, where he is responsible for Optum’s business strategy, public policy, corporate investment, research and development, acquisitions and corporate governance .

Prior to this role, Slavitt was CEO of OptumInsight from 2006 through 2011and has served in other roles at UnitedHealth Group, such as leading the consumer solutions business and co-chairing UnitedHealth Group’s Innovation Council . Previously, Slavitt was founder and CEO of Health Allies, which was acquired by UnitedHealth Group in 2003 . He also has worked as a strategy consultant with McKinsey & Company and as an investment banker with Goldman Sachs .

Slavitt serves in a number of advocacy and board capacities in healthcare, education and the community . He is a senior advisor to Hope Street Group; on the steering committee of the Itasca Project; on the Major Gift Committee at the University of Pennsylvania, where he also was co-chair of annual giving; serves on the board of directors of the Guthrie Theatre; and is a director at Capella University (NASDAQ: CPLA) where he is chair of the compensation committee . Slavitt graduated from the Wharton School and The College of Arts & Sciences at the University of Pennsylvania, and received his Master of Business Administration degree from the Harvard Business School .

Jeffrey Townsend, executive vice president, chief of staff, is responsible for a wide swath of Cerner business, including supervision of Cerner LifeSciences, Healthe™ Employer, and much of Cerner’s cloud computing effort, the foundation for our consumer presence. These market initiatives are referred to as CERN—an acronym for Consumer, Employer, Research and Networks—and are critical to Cerner’s vision for population health. The CERN structure also encompasses Cerner’s Revenue Cycle, EMEA (Europe, Middle East and Africa) and Lighthouse clinical process improvement organizations, to establish future strategic alignment between U.S. and European health care systems. Townsend is also the senior executive responsible for the Tiger Institute and the University of Missouri Health System, Cerner’s second charterITWorks™ client. He also oversees Catalyst, an organization that works across Cerner supporting front line teams and clients with a blend of education, communication and marketing expertise. Additionally, Townsend focuses much of his time on the innovation, strategy and direction of Cerner solutions, financial planning and overseeing the company’s day-to-day operations as CEO Neal Patterson’s proxy. Townsend joined Cerner in 1985 as a programmer analyst, and within one year, he was named project leader of the foreign systems interface engineering team. After leaving Cerner for several years to lead a family-owned business, Townsend rejoined the company as project manager for strategic systems and product line executive for Cerner’s management systems. He also served as the chief engineering officer, where he oversaw product development of Cerner Millennium® “I am proud of what we have achieved with Millennium, but I believe there are more big ideas yet to come,” Townsend said. “After more than 30 years, Cerner is in a unique position to be able to help define and create an ideal future state where health care is simplified by connecting individuals, providers, researchers and employers to impact health outcomes.” Townsend earned a bachelor’s degree in computer science from Iowa State University.

Andy Slavitt Group Executive Vice President Andy Slavitt is group executive vice president at Optum, where he is responsible for Optum’s business strategy, public policy, corporate investment, research and development, acquisitions and corporate governance. Prior to this role, Slavitt was CEO of OptumInsight from 2006 through 2011and has served in other roles at UnitedHealth Group, such as leading the consumer solutions business and co-chairing UnitedHealth Group’s Innovation Council.

Previously, Slavitt was founder and CEO of Health Allies, which was acquired by UnitedHealth Group in 2003. He also has worked as a strategy consultant with McKinsey & Company and as an investment banker with Goldman Sachs. Slavitt serves in a number of advocacy and board capacities in health care, education and the community. He is a senior advisor to Hope Street Group; on the steering committee of the Itasca Project; on the Major Gift Committee at the University of Pennsylvania, where he also was co-chair of annual giving; serves on the board of directors of the Guthrie Theatre; and is

Jeffrey TownsendExecutive Vice President, Chief of StaffCerner Corp .

Jeffrey Townsend, executive vice president, chief of staff, is responsible for a wide swath of Cerner business, including supervision of Cerner LifeSciences, Healthe™ Employer, and much of Cerner’s cloud computing effort, the foundation for Cerner’s consumer presence . Townsend is also the senior executive responsible for the Tiger Institute and the University of Missouri Health System, Cerner’s second charterITWorks™ client . He also oversees Catalyst, an organization that works across Cerner supporting front line teams and clients with a blend of education, communication and marketing expertise . Additionally, Townsend focuses much of his time on the innovation, strategy and direction of Cerner solutions, financial planning and overseeing the company’s day-to-day operations as CEO Neal Patterson’s proxy .

Townsend earned a bachelor’s degree in computer science from Iowa State University .

24


Mark Turco, M.D. Chief Medical OfficerCovidien plc

Mark Turco is responsible for providing Covidien’s vascular therapies business with council and collaboration in areas of medical affairs globally, including clinical affairs, health economics & reimbursement, Professional Affairs and Clinical Education (PACE) as well as partnering with Covidien’s ventures and business development groups . He also oversees Vascular Therapies’ commitment to patient safety and post market surveillance . In January of 2013, Turco was appointed an Executive-In-Residence for Covidien’s internal program looking at new strategic areas for investment within the vascular space .

Prior to joining Covidien, Turco practiced as an interventional cardiologist in the Washington, D .C . area for the past 11 years where he led clinical trial research and was active in patient care . In May 2011, Turco left clinical practice to take on his new role as chief medical officer for vascular therapies within Covidien . This role, in part, allows Turco to help share his medical expertise with the Covidien teams to help promote safe, effective, innovative technologies that could impact all of society .

Turco received his bachelor’s degree from the University of Pennsylvania . He received his medical degree and internal medicine training at the George Washington University in Washington, D .C . Turco completed his cardiology training at Temple University Hospital in Philadelphia, Pa . Turco is board certified in cardiology and interventional cardiology .

25


David AmsellemSenior Research AnalystPiper Jaffray & Co .

David Amsellem is a managing director and senior research analyst at Piper Jaffray covering specialty pharmaceuticals .

Prior to joining Piper Jaffray in 2008, Amsellem spent five years at Friedman Billings Ramsey, where he was a senior research analyst covering small- and mid-cap pharmaceuticals from 2006-2008 and a senior associate on the biotechnology equity research team from 2003-2006 . Amsellem was recognized as the No . 1 ranked analyst in North America for accuracy of earnings estimates in the pharmaceuticals sector in the 2008 Financial Times/StarMine “Best Brokerage Analyst” survey . Amsellem has more than 10 years of Wall Street experience, including work in life sciences investment and merchant banking at Prudential Vector Healthcare .

Amsellem graduated from Cornell University with a bachelor’s degree in industrial relations .

Charles DuncanSenior Research AnalystPiper Jaffray & Co .

Charles Duncan, Ph .D ., joined Piper Jaffray in 2012 as a managing director and senior research analyst focused on small- and mid-cap emerging growth biotechnology companies . Duncan brings more than 17 years of sell-side experience during which he has covered a broad range of biopharma companies, most recently serving as an analyst at JMP Securities since 2002 .

Previously, Duncan covered the sector at Dresdner Kleinwort Wasserstein, Vector Healthcare Group - Prudential Securities, Tucker Anthony Cleary Gull and Chatfield Dean & Co . Duncan has been recognized by industry sources, including the Financial Times and StarMine Analyst Awards, as being among the best analysts for his fundamental and timely analysis . Duncan began his career as a manager of clinical development at Global Drug Development, Inc ., a pharmaceutical development consulting firm, and he also launched InfusionVision Medical, a venture-backed start-up medical device company .

Duncan is a graduate of the University of Wisconsin-Madison and holds a doctorate in pharmaceutical sciences with a concentration in neuropharmacology from the University of Colorado .

Piper Jaffray Senior Research Analyst Biographies

26


Kevin EllichSenior Research AnalystPiper Jaffray & Co .

Kevin Ellich is a principal and senior research analyst at Piper Jaffray covering healthcare services and alternative site providers . With more than 10 years of industry experience on both the buy- and sell-side, Ellich’s coverage universe includes clinical/diagnostic labs, dialysis, ambulatory surgery centers, home health, physician practice management/hospital outsourcing companies, and other alternative site providers .

Prior to joining Piper Jaffray in April 2011, Ellich had a short stint at Collins Stewart and spent four years at RBC Capital Markets covering healthcare providers and services . Ellich also worked at American Express Financial Advisors, Wachovia Securities and hedge fund Aplos Advisors .

Ellich holds a bachelor’s degree in business from the University of Minnesota .

Thomas GundersonSenior Research AnalystPiper Jaffray & Co .

Thomas Gunderson is a managing director and senior research analyst at Piper Jaffray, following medical technology companies . In more than 20 years as an analyst, Gunderson has been recognized by several industry publications, including The Wall Street Journal, Institutional Investor, First Call, and Medical Device and Diagnostic Industry . In 2010, Thomson/Reuters recognized him as one of the “Top Ten Overall Earnings Estimators” across all stock sectors .

Gunderson holds a bachelor’s degree from Carleton College and graduate degrees in cell biology and business administration .

27


Matt MiksicSenior Research AnalystPiper Jaffray & Co .

Matt Miksic is a managing director and senior research analyst at Piper Jaffray, covering medical technology and hospital supply stocks .

Miksic joined Piper Jaffray after spending eight years in equity research at Morgan Stanley, where he was a member of the medical technology and hospital supply coverage team since 2002, with lead coverage of orthopaedics, spine and hospital supplies . Prior to Morgan Stanley, Miksic was a senior manager with Arthur Andersen in its business consulting division, and spent five years with a software startup .

Miksic holds a bachelor’s degree in computer science from Rutgers College and a master of business administration degree from the Leonard N . Stern School of Business at New York University .

William QuirkSenior Research AnalystPiper Jaffray & Co .

William Quirk is a managing director and senior research analyst at Piper Jaffray, focusing on the medical diagnostics and life science tools sectors .

Prior to joining Piper Jaffray in 2006, Quirk worked in equity research at RBC Capital Markets in Minneapolis and at Paine Webber in New York . In 2012, he was named the 2012 most accurate earnings forecaster for the Life Science Tools industry by Starmine .

Quirk received a bachelor’s degree in business from St . Norbert College and a Master of Business Administration degree from the Carlson School of Management at the University of Minnesota . He holds the Chartered Financial Analyst designation .

28


Ian SomaiyaSenior Research AnalystPiper Jaffray & Co .

Ian Somaiya is a managing director and senior research analyst at Piper Jaffray covering the biotechnology industry .

Prior to joining Piper Jaffray in 2010, Somaiya worked in equity research at Thomas Weisel Partners . Somaiya was recognized as “Best on the Street” by The Wall Street Journal in 2006, 2007 and 2009 for his biotechnology coverage . Formerly, Somaiya was a senior analyst at Morgan Stanley with responsibilities for small- and mid-capitalization biotechnology companies . He spent a year with The Carson Group in its healthcare consulting practice prior to making his transition to the sell-side at Prudential Securities .

Somaiya received a bachelor of arts degree in biology/neuroscience from New York University .

Edward Tenthoff Senior Research AnalystPiper Jaffray & Co .

Ted Tenthoff is a managing director and senior research analyst at Piper Jaffray, focused on the drug discovery sector of the biotech industry . In April 2013, Tenthoff moderated a cardiovascular medicine panel at the International Adult Stem Cell Conference at the Vatican . He was ranked No . 2 Stock Picker in biotechnology by the 2012 Wall Street Journal “Best on the Street” survey and was ranked No . 1 stock picker for the life science tools and services sector in the 2006 Starmine Analyst Awards .

Prior to joining Piper Jaffray in 2003, he covered the genomics sector at Robertson Stephens & Company, and was a medical technology analyst at Lehman Brothers .

Tenthoff received a bachelor’s degree in international relations from the University of Pennsylvania .

29


Brooks WestSenior Research AnalystPiper Jaffray & Co .

Brooks West is a principal and senior research analyst at Piper Jaffray covering medical technology companies with a focus on cardiovascular and related therapeutic categories . West leverages his prior experience as the director of marketing and business development at a medical device company, along with an extensive network of physician and industry relationships, to provide a unique perspective on the medtech sector .

Prior to joining Piper Jaffray in 2011, West covered medical technology for four years at Craig-Hallum Capital, and has in total 20 years of financial and medtech industry experience .

West received a bachelor’s degree from the Boston University School of Management .

Sean WielandSenior Research AnalystPiper Jaffray & Co .

Sean Wieland is a managing director and a senior research analyst at Piper Jaffray, focusing on healthcare information technology and healthcare services . Wieland has 20 years’ experience in healthcare information technology, including direct industry experience and more than 12 years on the sell side, and is a three-time Wall Street Journal “Best on the Street” award winner and Starmine award winner for earnings accuracy .

Prior to joining Piper Jaffray in 2005, Wieland was a senior research analyst at WR Hambrecht and Prudential Securities . Prior to joining the sell-side, he spent seven years in the industry, working in multiple roles at IDX Systems Corporation, most recently as a senior sales executive, where he learned firsthand about the need for technology in the healthcare setting .

Wieland earned his Master of Business Administration degree and bachelor’s degree in electrical engineering from the University of Vermont .

30


Attendee List

Name CompanyChris Abbott Piper Jaffray & Co .Julian Adams, Ph .D . Infinity Pharmaceuticals, Inc .Norman Alpert Vestar Capital PartnersDenise Anderson, Ph .D . Sit Investment Associates, Inc .Kelli Andreen Piper Jaffray & Co .Jeff Bakke Evolution1Steve Berg Piper Jaffray & Co .Todd Berg Torax Medical, Inc .Brad Berning Pine RiverRobert Blinn Pura Vida InvestmentsDean Briesemeister Boston Scientific CorporationKevin Broglio Thrivent Asset Management LLCSteve Bukowczyk Partner Fund Management, L .P .Frank Callaghan St . Jude Medical Inc .Michael Campbell Boston Scientific CorporationJeff Capello Boston Scientific CorporationMark Carlson, M .D . St . Jude Medical Inc .Michael Carrel AtriCureMike Carruthers Array BioPharma Inc .Jeff Carson Janus Capital ManagementChristopher Chavez TriVascular, Inc .Ted Christianson Piper Jaffray & Co .David Clair Piper Jaffray & Co .Joe Colletti Pine RiverWalter Colsman Columbia Management Investment Advisers, LLCPeter Day Piper Jaffray & Co .John DeFord, Ph .D . C . R . Bard, Inc .Bob DeSutter Piper Jaffray & Co .Jim Diedrich Nuveen Asset Management, LLCJim Douglas Piper Jaffray & Co .Scott Drake Spectranetics Corporation (The)Andrew Duff Piper Jaffray CompaniesBill Durkin Piper Jaffray & Co .Matthew Eirich The Advisory Board CompanyKevin Ellich Piper Jaffray & Co .Rachel Ellingson St . Jude Medical Inc .Joel Emery Fred Alger Management, Inc .Stacy Enxing Seng Covidien plcMatthew Farley Passaic Capital Management LLCJim Fehrenbach Piper Jaffray & Co .Joe Fleischhacker Lake Region MedicalBen Fleischman Decade CapitalChad Fugere Wells Capital Management

31


Lawrence Alexander Garcia, M .D . Steward Health Care SystemChris Gaulin MaverickAlex Gorsky Johnson & JohnsonClaudia Graham Dexcom, Inc .Dan Gulbrandson Piper Jaffray & Co .Thom Gunderson Piper Jaffray & Co .Adam Gunther Piper Jaffray & Co .George Halvorson Kaiser PermanenteSteve Hamil Winslow Capital ManagementCharles Hamilton Piper Jaffray & Co .Neil Hattangadi, M .D . Volcano CorporationMatt Hemsley Piper Jaffray & Co .Steve Hemsley UnitedHealth Group IncorporatedDavid Heupel Thrivent Asset Management LLCColin Hill GNS Healthcare, Inc .Sandy Hollenhorst Columbia Management Investment Advisers, LLCMichael Horowitz, M .D . UnitedHealth Group IncorporatedOmar Ishrak Medtronic, Inc .Brett Johnson Kopp Investment Advisors, LLCCraig Johnson Piper Jaffray & Co .Ryan Kaeding Piper Jaffray & Co .Alan Kaganov U .S . Venture PartnersDevesh Karandikar Lord Abbett & Company, LLCNeal Kaufman Baron CapitalAllan Kells Cerner CorporationJames King Columbia Management Investment Advisers, LLCJeff Klinefelter Piper Jaffray & Co .Gary Ko Franklin TempletonKevin Koch, Ph .D . Array BioPharma Inc .Michael Kramer TriVascular, Inc .Jason Kritzer Eaton Vance Management, Inc .Tim Kuehl Norwest Equity PartnersCole Lannum Covidien plcKurt Lauber Thrivent Asset Management, LLCLarry Lawson eCardioChris Leamon, Ph .D . Endocyte, Inc .Rick Leggott Arbor Capital Management, LLCBrian Lester Manning & NapierElizabeth Lilly GAMCOLarry Lin Columbia Management Investment Advisers, LLCXiang Liu BlackRock Advisors, LLCDon Longlet Next Century Growth Investors, LLCKyle Lottman Piper Jaffray & Co .John Lumbers Mackenzie Investments

32


Brad Maiers Piper Jaffray & Co .Matthew Margolis CriticalMassShar Matin Spectranetics Corporation (The)Kirk Mayer Wellington Management Company, LLCDavid Mays Kaiser PermanenteJohn McDermott Endologix Inc .Pat McKeegan Conatus CapitalPete McNerney Thomas, McNerney & PartnersRichard Migliori, M .D . UnitedHealth Group IncorporatedMatt Miksic Piper Jaffray & Co .Marco Minonne, CFA Neuberger Berman Group LLCJeff Mirviss Boston Scientific CorporationRoberto Morales Adage CapitalMichael Mueller Pine RiverDon Nathan UnitedHealth Group IncorporatedMarc Naughton Cerner CorporationNarendra Nayak Deerfield Management CompanyDavid Nazaret Wells Capital ManagementKirk Neilsen Versant Ventures, Inc .Tim Nelson Nuveen Asset Management, LLCAlex Nicolaou Capital Research Global InvestorsChristina O’Hara Ph .D . William Blair & CompanyTaylor O’Neill Pine RiverChristopher Owens IDEV Technologies, Inc .Steve Parente University of Minnesota, Department of Finance, Carlson School of ManagementSung Park Brown Investment Advisory & Trust CompanyNeal Patterson Cerner CorporationRick Pauls DiaMedicaDan Pelak Welsh Carson Anderson & StoweJ .P . Peltier Piper Jaffray & Co .John Penshorn UnitedHealth Group IncorporatedEd Quilty Derma Sciences, Inc .Bill Quirk Piper Jaffray & Co .Angie Raun Boston Scientific CorporationScott Ree Piper Jaffray & Co .Andrew Rem Nuveen Asset Management, LLCBob Rinek Piper Jaffray & Co .Paul Roach Cornerstone Capital ManagementHoward Root Vascular SolutionsSean Salmon Medtronic, Inc .Jon Salveson Piper Jaffray & Co .Luis Sanchez, M .D ., FACS Washington University School of Medicine in St . LouisChris Sassouni Eagle AssetTom Schnettler Piper Jaffray & Co .

33


Rob Schwartz M .D . AllinaJohn Seaberg NeoChord IncJake Seltz Wells Fargo Bank N .A .Will Sevush Piper Jaffray & Co .Jim Sexton Piper Jaffray & Co .David Shepley Arbor Capital Management, LLCAlex Slack MaverickAndy Slavitt OptumSam Smith Peregrine Capital ManagementPaul Sobotka Cibiem, Inc .Aaron Socker Wells Capital ManagementJason Sondell Norwest Equity PartnersSandeep Soorya Northern Trust InvestmentsKent Stanger Merit Medical Systems, Inc .David Stassen Split Rock Partners, LLCMike Steel TriVascular, Inc .Scott Sullivan Piper Jaffray & Co .Ben Sun Chartwell Investment Partners, L .P .Jill Swenson Boston Scientific CorporationDavid Therkelsen Waterstone Capital Management, L .P .Jeff Townsend Cerner CorporationThomas Trotter AngioScore, Inc .Kuhn Tsai OrbimedKathy Tune Thomas, McNerney & PartnersMark Turco, M .D ., FACC Covidien plcKen Turek Neuberger Berman Group LLCJohn Untereker eCardioDennis Wahr Holaira Inc .John Walcott Citadel Advisors LLCAndrew Warford MaverickJeff Warren Medtronic, Inc .JC Weigelt St . Jude Medical Inc .Brooks West Piper Jaffray & Co .Bob White TYRX, Inc .Joe Wilson UBS Global Asset ManagementSteph Wissink Piper Jaffray & Co .Matt Wittmer Wells Fargo Bank N .A .Jon Wood T . Rowe Price Associates, Inc .Jason Yeung MaverickChen Yu Vivo VenturesYi Zhou Surveyor Capital, LTDDon Zurbay St . Jude Medical Inc .

34


Downtown Minneapolis MapDowntown Minneapolis Map

1

Downtown Minneapolis Area Map

The Marquette Hotel

35


Downtown Minneapolis Skyway Map

Downtown Minneapolis Skyway Map

2

Minneapolis Skyway System

36


Restaurant List

WALKING DISTANCE FROM THE HOTEL

Vincent1100 Nicollet Avenue Minneapolis, MN 55403+1 612 630-1189www .vincentarestaurant .com

Manny’s825 Marquette Avenue S Minneapolis, MN 55402+1 612 339-9900www .mannyssteakhouse .com

Oceanaire50 S 6th Street Minneapolis, MN 55402+1 612 333-2277www .theoceanaire .com

SHORT TAXI RIDE FROM THE HOTEL

112 Eatery112 N 3rd Street Minneapolis, MN 55401+1 612 343-7696www .112eatery .com

The Bachelor Farmer50 2nd Avenue N Minneapolis, MN 55401+1 612 206-3920www .thebachelorfarmer .com

Bar La Grassa800 N Washington Avenue Minneapolis, MN 55401+1 612 333-3837www .barlagrassa .com

La Belle Vie510 Groveland Avenue Minneapolis, MN 55403+1 612 874-6440www .labellevie .us

Restaurant Alma528 SE 6th Avenue Minneapolis, MN 55414+1 612 379-4909www .restaurantalma .com

Since 1895. Member SIPC and NYSE. © 2013 Piper Jaffray & Co. 8/13 CM-13-0268 piperjaffray.com

MINNEAPOLIS – Headquarters

800 Nicollet Mall, Suite 1000Minneapolis, MN 55402+1 612 303-6000+1 800 333-6000

BOSTON

265 Franklin Street, Suite 710Boston, MA 02110+1 617 654-0721

CHICAGO

Hyatt Center, 24th Floor71 South Wacker DriveChicago, IL 60606+1 312 920-3200+1 800 973-1192

LONDON

13/F 88 Wood StreetLondon EC2V 7RS+44 207 796-8400

LOS ANGELES

633 W. 5th Street, Suite 2800Los Angeles, CA 90071+1 213 629-1031

NEW YORK

345 Park Avenue, Suite 1200New York, NY 10154+1 212 284-9300+1 800 982-0419

SAN FRANCISCO

345 California Street, Suite 2400San Francisco, CA 94104+1 415 616-1600+1 800 214-0540

ZURICH

Claridenstrasse 20CH-8002 Zurich+41 44 204-2424

Piper Jaffray Heartland Summit · 2013-08-12 · 3 1415 2013 Agenda The Minneapolis Club 729 Second...

Documents

Transcript of Piper Jaffray Heartland Summit · 2013-08-12 · 3 1415 2013 Agenda The Minneapolis Club 729 Second...